Bio-Thera Solutions Balance Sheet Health
Financial Health criteria checks 3/6
Bio-Thera Solutions has a total shareholder equity of CN¥847.3M and total debt of CN¥702.0M, which brings its debt-to-equity ratio to 82.8%. Its total assets and total liabilities are CN¥2.3B and CN¥1.5B respectively.
Key information
82.8%
Debt to equity ratio
CN¥701.97m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥451.10m |
| Equity | CN¥847.30m |
| Total liabilities | CN¥1.49b |
| Total assets | CN¥2.34b |
Recent financial health updates
Recent updates
We Think Bio-Thera Solutions (SHSE:688177) Has A Fair Chunk Of Debt
Dec 17
Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking
Oct 09Time To Worry? Analysts Just Downgraded Their Bio-Thera Solutions, Ltd. (SHSE:688177) Outlook
Sep 05Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely
Jun 06Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%
Apr 18Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%
Mar 04Financial Position Analysis
Short Term Liabilities: 688177's short term assets (CN¥1.0B) do not cover its short term liabilities (CN¥1.1B).
Long Term Liabilities: 688177's short term assets (CN¥1.0B) exceed its long term liabilities (CN¥410.8M).
Debt to Equity History and Analysis
Debt Level: 688177's net debt to equity ratio (29.6%) is considered satisfactory.
Reducing Debt: 688177's debt to equity ratio has increased from 11.3% to 82.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688177 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 688177 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 12:49 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio-Thera Solutions, Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Shitong Han | Citic Securities Co., Ltd. |
| Yinglan Shu | Haitong International Research Limited |